Bristol-Myers Goes After Celgene

Bristol-Myers to Buy Celgene

Bristol-Myers Squibb is making a $74 billion bet — and investors aren't pleased. The New York-based pharmaceutical giant on Thursday said it would acquire Celgene, a Summit, New Jersey-based cancer drug company, in a cash and stock deal valued at $74 billion...

By | January, 4, 2019|Categories: Articles, Featured|Tags: , , , , , , , |0 Comments

It’s a Rotten AAPL

Apple’s Stock Plunges

Apple had some news for investors to ring in 2019, only it wasn’t good. The company’s revenue this quarter will be significantly lower than it had previously indicated, thanks largely to a slowdown in China sales. Apple’s shares were halted after the stock market closed Wednesday...

By | January, 3, 2019|Categories: Articles, Featured|Tags: , , , , , , , , , , , , |0 Comments

Apple Guides Lower

Apple’s Mixed Results

Apple Inc. reported its fourth consecutive quarter of record revenue and profit, as the combination of higher iPhone prices and strong app-store sales propelled the technology giant to its best year ever. But the world’s most valuable company offered guidance for the current period that disappointed many investors and said it would stop reporting unit sales for its products...

By | November, 2, 2018|Categories: Articles, Featured|Tags: , , , , , , , , |0 Comments

What’s Next for Tesla?

Mixed Results for Tesla

Tesla Inc. reassured investors it would achieve a profit later this year, as a rush of Model 3 sales in the second quarter helped the electric-car maker burn less cash than expected. The results, which sent Tesla’s shares soaring in after-hours trading Wednesday, should give Chief Executive Elon Musk some wiggle room...

By | August, 2, 2018|Categories: Articles, Featured|Tags: , , , , , , , |0 Comments